CLLS
Cellectis S.A.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | Q2 2026 | — | +0% |
| Millennium Management | Q1 2025 | Q1 2026 | — | +0% |
| Two Sigma Investments | Q3 2024 | Q2 2025 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Cellectis S.A.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Oct 20, 2020 — the most recent Form 4 on file — not from today.
Fundamentals
XBRL · Cellectis S.A.Not enough XBRL history to plot. Cellectis S.A.hasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Cellectis S.A. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 6-KFORM 6-KJun 9, 2026
- 6-KInterim disclosure (foreign)May 21, 2026
- 6-KFORM 6-KMay 20, 2026
- 6-KFORM 6-KMay 12, 2026
- 6-KFORM 6-KMay 11, 2026
- 6-KInterim disclosure (foreign)May 11, 2026
- 6-KFORM 6-KMay 4, 2026
- 6-KFORM 6-KApr 27, 2026
- 6-KFORM 6-KApr 13, 2026
- 20-FAnnual report (foreign)Mar 20, 2026
- 6-KFORM 6-KMar 20, 2026
- 6-KFORM 6-KMar 12, 2026
- 6-KFORM 6-KJan 8, 2026
- 6-KFORM 6-KDec 15, 2025
- 6-KFORM 6-KDec 8, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | Q2 2026 | $0.00 | — | +0% |
| Citadel Advisors | Q4 2025 | open | $0.00 | — | +0% |
| Millennium Management | Q1 2025 | Q1 2026 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | Q2 2025 | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2024 | Q2 2025 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.